Australian Technical Advisory Group on Immunisation (ATAGI) advice for immunisation providers regarding the administration of seasonal influenza vaccines in 2017

Australia
NITAGs
6 March 2017

During its 62nd meeting in February 2017, ATAGI endorsed its recommendation for annual influenza vaccination for any person ≥6 months of age who wishes to reduce the likelihood of becoming ill with influenza.

drapeau-australie.jpg

Key points:

  • Annual vaccination is the most important measure to prevent influenza and its complications.
  • Annual influenza vaccination is recommended for any person ≥6 months of age who wishes to reduce the likelihood of becoming ill with influenza.
  • Recent evidence suggests protection against influenza may start to decrease from 3 to 4 months following vaccination and early vaccination needs to be balanced with this. While influenza continues to circulate, it is never too late to vaccinate.
  • Only quadrivalent influenza vaccines (QIV) formulations are available in Australia in 2017. Age restrictions apply according to vaccine brand (refer to Table 1).
  • QIVs are funded on the National Immunisation Program (NIP) in 2017 for the following groups:
    • Aboriginal and/or Torres Strait Islander children aged 6 months to <5 years
    • Aboriginal and/or Torres Strait Islander persons aged ≥15 years
    • All persons aged ≥65 years
    • All persons aged ≥6 months who have certain medical conditions which increase the isk of influenza disease complications; for example, severe asthma, lung or heart disease, low immunity or diabetes (refer to Table 3).
    • Pregnant women (during any stage of pregnancy).
  • Influenza vaccination is also strongly recommended, but not funded, for other groups who are at increased risk of influenza and its complications (refer to Table 3 footnote).
  • Persons with egg allergy, including anaphylaxis, can be safely vaccinated with influenza vaccines. Persons with a history of anaphylaxis to egg can be vaccinated with a full vaccine dose in medical facilities with staff experienced in recognising and treating anaphylaxis.
  • Providers are reminded to report all vaccines given to the Australian Immunisation Register.
Documents to download

Related News & Events

  • Australia
    Health policy

    The Australian Immunisation Handbook celebrates its 10th edition

    07.08.2017

    The Australian Immunisation Handbook provides clinical advice for health professionals on the safest and most effective use of vaccines in their practice. These recommendations are developed by Australian Technical Advisory Group on Immunisation (ATAGI) and approved by the National Health and Medical Research Council (NHMRC).

    Read more
  • Canada
    NITAGs

    NACI mandate expands to support local decision-making on vaccine programs

    28.07.2017

    In June 2016 the Public Health Agency of Canada (PHAC) announced that the mandate of Canada’s NITAG, the National Advisory Committee on Immunization (NACI) will be expanded. In addition to the assessment of vaccine characteristics (safety, efficacy, effectiveness, and immunogenicity), NACI will also be assessing additional programmatic elements including economic evaluations, feasibility of implementation, acceptability, ethics and equity. 

    Read more
  • NITAGs

    Launch of the Global National Immunization Technical Advisory Group Network

    05.07.2017

    The second Global National Immunization Technical Advisory Group Network (GNN) meeting was held in Berlin from 28-29 June. The meeting was jointly organized by WHO, the Robert Koch Institute, US Centers for Disease Control (CDC) and Prevention and Agence de Médecine Preventive−Health Policy and Institutional Development Center (AMP-HPID).

    Read more